Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction
1 other identifier
interventional
108
1 country
1
Brief Summary
The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 4, 2026
CompletedFirst Posted
Study publicly available on registry
March 10, 2026
CompletedStudy Start
First participant enrolled
April 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2026
March 10, 2026
March 1, 2026
6 months
March 4, 2026
March 4, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Live birth
The frequency of live birth will be noted. Delivery of a baby with signs of life at birth, irrespective of gestational age will be considered as live birth.
12 weeks
Low Birth weight
Frequency of low birth weight will be noted. Neonatal birth weight \<2.5 kg will be documented as low birth weight.
12 weeks
Secondary Outcomes (2)
Neonatal Intensive Care Unit Admission
7 days
Perinatal Mortality
7 days
Study Arms (2)
Enoxaparin Group
EXPERIMENTALPatients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery.
Standard Management Group
EXPERIMENTALPatients will continue with standard management alone.
Interventions
Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery
Patients will continue with standard management alone.
Eligibility Criteria
You may qualify if:
- Women aged 18-40 years
- Singleton pregnancy
- Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)
- Diagnosed with both IUGR and oligohydramnios
- Willing to provide informed written consent
You may not qualify if:
- Multiple gestation
- Major fetal congenital anomalies
- Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)
- Known coagulation disorders or contraindications to enoxaparin
- Women already on anticoagulation therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Combined Military Hospital
Quetta, Balochistan, 80000, Pakistan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Maimoona Hafeez
Combined Military Hospital Quetta
- STUDY DIRECTOR
Sidra Iqbal, FCPS
Combined Military Hospital Quetta
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Research Consultant
Study Record Dates
First Submitted
March 4, 2026
First Posted
March 10, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Last Updated
March 10, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
Data can be shared on a reasonable request.